Could XBiotech Inc. (XBIT) Lose Strenght? The Stock Increases A Lot Today

XBiotech Inc. (NASDAQ:XBIT) Logo

The stock of XBiotech Inc. (NASDAQ:XBIT) is a huge mover today! The stock increased 5.07% or $0.46 during the last trading session, reaching $9.53. About 165,361 shares traded or 3.13% up from the average. XBiotech Inc. (NASDAQ:XBIT) has risen 58.92% since September 13, 2018 and is uptrending. It has outperformed by 58.92% the S&P500.
The move comes after 6 months positive chart setup for the $390.84 million company. It was reported on Sep, 13 by We have $10.29 PT which if reached, will make NASDAQ:XBIT worth $31.27M more.

Analysts await XBiotech Inc. (NASDAQ:XBIT) to report earnings on October, 30. They expect $-0.15 earnings per share, down 7.14 % or $0.01 from last year’s $-0.14 per share. After $-0.16 actual earnings per share reported by XBiotech Inc. for the previous quarter, Wall Street now forecasts -6.25 % EPS growth.

More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: which released: “XBiotech Added to Russell 3000® Index Nasdaq:XBIT – GlobeNewswire” on June 11, 2019, also with their article: “XBiotech Announces Pricing of Public Offering of Common Shares – GlobeNewswire” published on May 31, 2019, published: “What Kind Of Investor Owns Most Of XBiotech Inc. (NASDAQ:XBIT)? – Yahoo Finance” on July 16, 2019. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: and their article: “Read This Before Selling XBiotech Inc. (NASDAQ:XBIT) Shares – Yahoo Finance” published on April 29, 2019 as well as‘s news article titled: “XBiotech Announces Public Offering of Common Shares – GlobeNewswire” with publication date: May 30, 2019.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $390.84 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.